CRX 527

CRX 527 is a ligand of TLR4 and also serves as an adjuvant for peptide-based cancer vaccines, showing potential to enhance anti-tumor immune responses. CRX 527 can also induce HSC differentiation, increase the proportion and quantity of LSK cells, and promote their differentiation into macrophages, activating immune defense and protecting intestinal epithelium from radiation damage[1][2].

Product Specifications

CAS Number

[216014-14-1]

UNSPSC

12352005

Target

Toll-like Receptor (TLR)

Related Pathways

Immunology/Inflammation

Field of Research

Cancer; Inflammation/Immunology

Smiles

CCCCCCCCCC(O[C@H](CCCCCCCCCCC)CC(O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1OP(O)(O)=O)CO)OC[C@@H](C(O)=O)NC(C[C@@H](CCCCCCCCCCC)OC(CCCCCCCCC)=O)=O)NC(C[C@@H](CCCCCCCCCCC)OC(CCCCCCCCC)=O)=O)=O)=O

Molecular Formula

C81H151N2O19P

Molecular Weight

1488.04

References & Citations

[1]Dongshu Liu, et al. CRX-527 induced differentiation of HSCs protecting the intestinal epithelium from radiation damage. Front Immunol. 2022 Aug 30;13:927213.|[2]Elena Tondini, et al. Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control. NPJ Vaccines. 2022 Jun 23;7 (1) :64.